Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H26N2O2 |
Molecular Weight | 278.3898 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1
InChI
InChIKey=OWQIUQKMMPDHQQ-UHFFFAOYSA-N
InChI=1S/C16H26N2O2/c1-5-18(6-2)11-16(3,4)12-20-15(19)13-7-9-14(17)10-8-13/h7-10H,5-6,11-12,17H2,1-4H3
Molecular Formula | C16H26N2O2 |
Molecular Weight | 278.3898 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Dimethocaine (DMC, larocaine), a synthetic derivative of cocaine, is a widely distributed "legal high" consumed as a "new psychoactive substance" (NPS), originally was used in the 1930s as an anesthetic, primarily in dentistry, ophthalmology, and otolaryngology. This drug completely inhibits dopamine transporter and has had the potential for abuse. Dimethocaine is intended for forensic and research purposes.
Originator
Sources: https://thedrugclassroom.com/video/dimethocaine/
Curator's Comment: # Hoffmann-La Roche Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7635175 |
1.2 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
in rhesus monkeys: When responding was stable, dimethocaine (0.030-1.7 mg/kg/ infusion) was substituted for the cocaine training dose. Dimethocaine administration produced higher response rates compared with that of procaine, and was a more potent reinforcer. Drug effects on behavior were related to DAT occupancy in monkey striatum during neuroimaging with positron emission tomography (PET). DAT occupancy was determined by displacement of 8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane (FECNT). DAT occupancy was between 66 and 82% and <10-41% for doses of dimethocaine and procaine that maintained maximum response rates, respectively.
Acute administration of dimethocaine (10-40 mg/kg, IP) significantly increased locomotor activity and time spent on the drug-paired side and reduced the relative number of entries and time spent on the open arms of the plus-maze in mice.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7635175
Dimethocaine showed full displacement of [3H]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane 1.5-naphthalenedisulfonate (CFT) binding (0-30 microM tested) and full inhibition of dopamine uptake (0-100 microM tested). Dimethocaine was only slightly less potent than cocaine with an estimated Ki of 1.4 micorM and an IC50 value of 1.2 microM for [3H]CFT binding and dopamine uptake.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:06:09 GMT 2023
by
admin
on
Fri Dec 15 17:06:09 GMT 2023
|
Record UNII |
R3L4A6GOWZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Dimethocaine
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
68927
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
100000079208
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
Dimethocaine
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
m4512
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
94-15-5
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
3154
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
R3L4A6GOWZ
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
C98208
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
SUB13607MIG
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
DTXSID40240185
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY | |||
|
7177
Created by
admin on Fri Dec 15 17:06:09 GMT 2023 , Edited by admin on Fri Dec 15 17:06:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |